November 2019 Vol 10, No 11

Many breast cancer survivors experience changes in their sexual health related to cancer treatment.
Studies demonstrate that many gynecological (Gyn) cancer patients are reluctant to exercise during and after treatment due to fatigue and general weakness. This is the most distressing symptom affecting their quality of life.
Our team implemented a survivorship needs assessment in the Dallas-Fort Worth area to determine the specific needs of the cancer survivors in a specified geographic area.
The Academy of Oncology Nurse & Patient Navigators (AONN+) promotes the goal to share best practices for survivorship and to address the question “Does the Survivorship Care Plan (SCP) Meet Patient Goals?” (Staci Oertle, RN, MSN, APN, AOCNP, AONN+ Survivorship Committee).
Survivorship care plans (SCPs) have played an important role in cancer care for over a decade and are included in the quality metrics or accreditation standards of several institutions, including the American College of Surgeons Commission on Cancer (ACS CoC).
Activating mutations in PIK3CA (the gene encoding the p110α catalytic subunit of class I phosphatidylinositol 3-kinase [PI3K] [PI3Kα]) lead to increased activity of the PI3K pathway and play a role in endocrine treatment resistance in breast cancer.
Evidence exists showing that enabling patients to engage in treatment decisions through education and shared decision-making is an effective tool in promoting self-efficacy, reducing barriers to care, and increasing the perceived benefits of self-involvement in one’s cancer diagnosis and treatment plan.
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.
Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/K–mutant stage III melanoma.
Page 3 of 3
Results 61 - 78 of 78

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country